Role of Milrinone in Septic Myocardial Depression

Authors

  • Vinko Tomicic

Abstract

At present, myocardial depression (MD) in septic shock (SS) is more frequently recognized. In 1984, Parker et al. published 20 patients with SS where 50% of them showed a left ventricular ejection fraction (LVEF) less than 40% 1 . It was not until 2006 that it became more widely accepted that some degree of MD was present in this kind of patients 2 . However, the prevalence has been variable depending on the evaluation method, either through cardiac output (CO), measurement of troponins, B type Natriuretic Peptide or by echocardiography 2-4 . In 2008 Vieillard-Baron et al. studied 67 patients with SS without a history of heart disease with transesophageal echocardiography. They estimated a mean incidence of MD greater than 60%, which manifests itself in the first 48 hours of evolution and recovers between seven and ten days after the onset of SS 5 .

References

M M Parker, J H Shelhamer, S L Bacharach, M V Green, C H Natanson, T M Frederick, et al (1984) Profound but reversible myocardial depression in patients with septic shock. 100(4), 483-440.

M Maeder, T Fehr, H Rickli, P Ammann (2006) Sepsis associated myocardial dysfunction: Diagnostic and prognostic impact of Cardiac Troponins and Natriuretic Peptides. 129(5), 1349-1366.

A Vieillard-Baron, S Prin, K Chergui, O Dubourg, F Jardin (2003) Hemodynamic Instability in Sepsis. Bedside Assessment by Doppler Echocardiography. 168(11), 1270-1276.

E Antonucci, E Fiaccadori, K Donadello, F S Taccone, F Franchi, S Scolletta (2014) Myocardial depression in sepsis: from pathogenesis to clinical manifestations and treatment. 500-511.

A Vieillard-Baron, V Caille, C Charron, G Belliard, B Page (2008) Actual incidence of global left ventricular hypokinesia in adult septic shock. 36, 1701-1706.

F Jardin, T Fourme, B Page, Y Loubières, A Vieillard-Baron, A Beauchet, et al (1999) Persistent preload defect in severe sepsis despite fluid loading: A longitudinal echocardiographic study in patients with septic shock. 116(5), 1354-1359.

JE Parrillo, C Burch, JH Shelhamer, MM Parker, C Natanson, W Schuette (1985) A circulating myocardial depressant substance in humans with septic shock: septic shock patients with reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance. 76, 1539-1553.

DL Maass, J White, JW Horton (2002) IL-1beta and IL-6 act synergistically with TNF-alpha to alter cardiac contractile function after burn trauma. 18(4), 360-366.

KR Walley (2017) New Approaches to Modifying Inotropy in Sepsis-Induced Myocardial Dysfunction. 45(4), 754-756.

EY Davani, JH Boyd, DR Dorscheid, et al (2006) Cardiac ICAM-1 mediates leukocyte-dependent decreased ventricular contractility in endotoxemic mice. 72, 134-142.

S Price, PB Anning, JA Mitchell, TW Evans (1999) Myocardial dysfunction in sepsis: mechanisms and therapeutic implications. 20, 715-724.

P Steendijk (2006) The role of nitric oxide signaling in sepsis-induced myocardial dysfunction. 34(1), 255-257.

RE Cunnion, GL Schaer, MM Parker, C Natanson, JE Parrillo (1986) The coronary circulation in human septic shock. 73(4), 637-644.

(2021) Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock. 49(11), e1063-e1143.

M Böhm, R Kirchmayr, P Gierschik, E Erdmann (1995) Increase of myocardial inhibitory G-proteins in catecholamine refractory septic shock or in septic multiorgan failure. 98, 183-186.

N Jindal, SM Hollenberg, RP Dellinger (2000) Pharmacologic issues in the management of septic shock. 16, 233-249.

S Krishnagopalan, A Kumar, JE Parrillo, A Kumar (2002) Myocardial dysfunction in the patient with sepsis. 8(5), 376-388.

S Lindgren, P Almqvist, D Arvidsson, A Montgomery, KE Andersson, U Haglund (1990) Lack of beneficial effects of milrinone in severe septic shock. 31(4), 365-375.

E Wilkman, KM Kaukonen, V Pettila, A Kuitunen, M Varpula (2013) Association between inotrope treatment and 90-day mortality in patients with septic shock. 57(4), 431-442.

V Tomicic, L Zouein, J Espinoza, S Ugarte (2015) Milrinone role in treatment of septic shock. 19(1), p154.

J-M Liet, C Jacqueline, JL Orsonneau, Ch Gras-LeGuen, G Potel, J-Ch Roz%C3%A9 (2005) The effects of milrinone on hemodynamics in an experimental septic shock model. 6, 195-199.

M Sakai, T Suzuki, K Tomita, S Yamashita, S Palikhe, K Hattori (2017) Diminished Responsiveness to Dobutamine as an Inotrope in Mice with Cecal Ligation and Puncture Induced Sepsis: Attribution to Phosphodiesterase 4 Up-regulation. 312(6), H1224-H1237.

Z Wang, Q Wu, X Nie, J Guo, C Yang (2015) Combination Therapy with Milrinone and Esmolol for Heart Protection in Patients with Severe Sepsis: A Prospective Randomized Trial. 35(11), 707-716.

C A Schmittinger, M W Dünser, M Haller, H Ulmer, G Luckner, C Torgersen (2008) Combined milrinone and enteral metoprolol therapy in patients with septic myocardial depression. 12, R99.

V Tomicic, J Guerrero (2005) Endotelio y Sepsis. 29(3), 142-150.

J C Jentzer, J C Coons, C B Link, M Schmidhofer (2015) Pharmacotherapy Update on the Use of Vasopressors and Inotropes in the Intensive Care Unit. 20(3), 249-260.

J Ossinen, V P Harjola, K Siirila-Waris, J Lassus, J Melin, K Peuhkurinen (2008) The use of more than one inotrope in acute heart failure is associated with increased mortality: a multicentre observational study. 10(4), 209-213.

W S Colucci, R F Wright, B E Jaski, M A Fifer, E Braunwald (1986) Milrinone and dobutamine in severe heart failure: Differing hemodynamic effects and individual patient responsiveness. 73(s3), III175-III183.

W S Colucci, A R Denniss, G F Leatherman, R J Quigg, D F Gauthier (1988) Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure. Dose-response relationships, correlation with circulating catecholamines, and effect of phosphodiesterase inhibition. 81(4), 1103-1110.

A Meissner, G Herrmann, L Gerdesmeyer, R Simon (1992) Additive effects of milrinone and dobutamine in severe heart failure. 81(5), 266-271.

J Poelaert, C Declerck, D Vogelaers, F Colardyn, C A Visser (1997) Left ventricular systolic and diastolic function in septic shock. 23(5), 553-560.

D Barraud, V Faivre, T Damy, S Welschbillig, E Gayat, C Heymes (2007) Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide treated rabbits: Comparison with dobutamine and milrinone. 35, 1376-1382.

S A Geraci (1994) Pharmacologic approach in patients with heart failure. 80-94.

W Chang, J F Xie, J Y Xu, Y Yang (2018) Effect of levosimend%C3%A1n on mortality in severe sepsis and septic shock: a meta-analysis of randomised trials. 8(3), e019338. https://doi.org/10.1136/bmjopen-2017-019338

F Feng, Y Chen, M Li, J J Yuan, X N Chang, C M Dong (2019) Levosimendan does not reduce the mortality of critically ill adult patients with sepsis and septic shock: A meta analysis. 132(10), 1212-1217.

J B Meng, M H Hu, Z Z Lai, C L Ji, X J Xu, G Zhang, S Tian (2016) Levosimendan Versus Dobutamine in Myocardial Injury Patients with Septic Shock: A Randomized Controlled Trial. 22, 1486-1496.

A Deep, C D Goonasekera, Y Wang, J Brierley (2013) Evolution of haemodynamics and outcome of fluid-refractory septic shock in children. 39, 1602-1609.

LJMHR Volume 23 Issue 4

Downloads

Published

2023-05-05

Issue

Vol. 23 No. 4 (2023): LJMHR Volume 23 Issue 4

Section

Articles

License

Copyright (c) 2023 Authors and Global Journals Private Limited

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

Role of Milrinone in Septic Myocardial Depression. (2023). London Journal of Medical and Health Research, 23(4), 27-31. https://journalspress.uk/index.php/LJMHR/article/view/324